MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-227.32M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.93 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -82.53% |
| Return on Assets (Trailing 12 Months) | -58.17% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.56 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.23 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.84 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 85.11M |
| Free Float | 76.26M |
| Market Capitalization | $1.28B |
| Average Volume (Last 20 Days) | 1.42M |
| Beta (Past 60 Months) | 1.04 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 93.85% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |